Lipopolysaccharide stimulates dynamic changes in B cell metabolism to promote proliferation

Curation statements for this article:
  • Curated by eLife

    eLife logo

    eLife Assessment

    This work reveals metabolic pathways and molecular events mechanistically linked to B cell activation. Using an unbiased, comprehensive proteome profiling method and various functional validation approaches, this study generated convincing evidence suggesting a role for amino acid uptake, cholesterol accumulation, and protein prenylation in the proliferation, survival, and biogenesis of B cells stimulated with LPS and other activating stimuli. The significance of the findings is considered to be fundamental, in that they will advance our understanding of cell metabolism during B cell activation.

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

Naïve B cells exit quiescence and enter a proliferative state upon activation, ultimately differentiating into antibody-secreting or memory B cells. Toll-like receptor (TLR) ligands, such as lipopolysaccharide (LPS), can serve as physiological stimuli to initiate this transition. Using quantitative proteomics, we show that TLR4 engagement induces metabolic reprogramming in murine B cells, increasing the expression of amino acid transporters and cholesterol biosynthetic enzymes. The amino acid transporter SLC7A5 is markedly upregulated following LPS stimulation, and conditional deletion of Slc7a5 impairs B cell proliferation, underscoring its essential role in B cell activation. LPS also elevates intracellular cholesterol levels, and inhibition of the rate-limiting enzyme HMG-CoA reductase blocks proliferation. This effect was mediated by a dual requirement for cholesterol metabolism and protein prenylation downstream of HMG-CoA reductase. Notably, this was not unique to TLR4 signalling but is also observed in B cells activated via TLR7, TLR9, CD40, or the B cell receptor. Together, these findings reveal that metabolic rewiring, including amino acid uptake and cholesterol metabolism, is an essential feature of B cell activation and proliferation.

Article activity feed

  1. Author response:

    Reviewer #1:

    We agree with the reviewer that a limitation of our study is its focus on cell-based assays rather than in vivo experiments. We did consider evaluating the effects of statins on B cell responses in vivo; however, this approach is complicated by findings that statins can influence antigen presentation by dendritic cells, thereby impacting antibody responses (Xia et al, 2018). One possible solution would be to use B cell-specific conditional knockout models to study the roles of the identified proteins in an in vivo context. However, we currently do not have access to these models and were therefore unable to include such experiments within a feasible timeframe. We will revise the discussion section to acknowledge these points.

    The reviewer also noted that our study assessed the roles of HMGCR, SQLE, and prenylation in B cell activation using pharmacological inhibitors and genetic knockdown/out approaches. Loss-of-function techniques such as RNAi, siRNA, and CRISPR can be challenging to apply to primary B cells, but we are exploring their feasibility for future revisions. While we acknowledge the limitations of using pharmacological inhibitors, we have taken several steps to mitigate these, including targeting multiple steps in the cholesterol biosynthetic pathway using structurally distinct inhibitors and conducting rescue experiments by supplementing downstream metabolites. To further investigate potential off-target effects of statins, we have recently performed proteomic analysis of B cells treated with and without fluvastatin. The data suggest that fluvastatin primarily affects cholesterol metabolism and does not cause widespread off-target effects. We will include this new data in the revised manuscript.

    Reviewer #2:

    The reviewer suggested that the study would be strengthened by determining whether the observed changes are specific to LPS + IL-4 stimulation or represent a more general B cell response to mitogenic signals.

    A complementary study by James et al. (James et al, 2024) investigated murine B cells stimulated via the B cell receptor (BCR) and CD40, using anti-IgM and anti-CD40 antibodies alongside IL-4. Their proteomic analysis showed that such co-stimulation induces a fivefold increase in total cellular protein mass within 24 hours, mirroring our findings with LPS + IL-4. They also reported upregulation of proteins associated with cell cycle progression, ribosome biogenesis, and amino acid transport. Furthermore, by using SLC7A5 knockout mice, they demonstrated that this transporter is required for B cell activation. We will expand our discussion to include and these findings. We will also expand on the final figure in our paper showing that the effects of statins are not limited to LPS.

    References:

    James O, Sinclair LV, Lefter N, Salerno F, Brenes A & Howden AJM (2024) A proteomic map of B cell activation and its shaping by mTORC1, MYC and iron. bioRxiv 2024.12.19.629506 doi:10.1101/2024.12.19.629506 [PREPRINT]

    Xia Y, Xie Y, Yu Z, Xiao H, Jiang G, Zhou X, Yang Y, Li X, Zhao M, Li L, et al (2018) The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell 175: 1059-1073.e21

  2. eLife Assessment

    This work reveals metabolic pathways and molecular events mechanistically linked to B cell activation. Using an unbiased, comprehensive proteome profiling method and various functional validation approaches, this study generated convincing evidence suggesting a role for amino acid uptake, cholesterol accumulation, and protein prenylation in the proliferation, survival, and biogenesis of B cells stimulated with LPS and other activating stimuli. The significance of the findings is considered to be fundamental, in that they will advance our understanding of cell metabolism during B cell activation.

  3. Reviewer #1 (Public review):

    The work presented by Cheung et al. used a quantitative proteomics method to capture molecular changes in B cells exposed to LPS and IL-4, a combination of stimuli activating naive B cells. Amino acid transporters, cholesterol biosynthetic enzymes, ribosomal components, and other proteins involved in cell proliferation were found to increase in stimulated B cells. Experiments involving genetic loss-of-function (SLC7A5), pharmacological inhibition (HMGCR, SQLE, prenylation), and functional rescue by metabolites (mevalonate, GGPP) validated the proteomics data and revealed that amino acid uptake, cholesterol/mevalonate biosynthesis, and cholesterol uptake played a crucial role in B cell proliferation, survival, biogenesis, and immunoglobulin class switching. Experiments involving cholesterol-free medium showed that both biosynthesis and LDLR-mediated uptake catered to the cholesterol demand of LPS/IL-4-stimulated B cells. A role for protein prenylation in LDLR-mediated cholesterol uptake was postulated and backed by divergent effects of GGPP rescue in the presence and absence of cholesterol in culture medium.

    Strengths:

    The discovery was made by proteome-wide profiling and unbiased computational analysis. The discovered proteins were functionally validated using appropriate tools and approaches. The metabolic processes identified and prioritized from this comprehensive survey and systematic validation are highly likely to represent mechanisms of high importance and influence. Analysis of immune cell metabolism at the protein level is relatively compared to transcriptomic and metabolomic analysis.

    The conclusions from functional validation experiments were supported by clear data and based on rational interpretations. This was enabled by well-established readouts/analytical methods used to analyze cell proliferation, viability, size, cholesterol content, and transporter/enzyme function. The data generated from these experiments strongly support the conclusions.

    This work reveals a complex, yet intriguing, relationship between cholesterol metabolism and protein prenylation as they serve to promote B cell activation. The effects of pharmacological inhibition and metabolite replenishment on the cholesterol content and activation of B cells were precisely determined and logically interpreted.

    Weaknesses:

    The findings of this study were obtained almost exclusively from ex vivo B cell stimulation experiments. Their contribution to B cell state and B-cell-mediated immune responses in vivo was not explored. Without in vivo data, the study still provides valuable mechanistic information and insights, but it remains unknown, and there is no discussion about how the identified mechanisms may play out in B cell immunity.

    The role of HMGCR, SQLE, and prenylation in B cell activation was assessed using pharmacological inhibitors. Evidence from other loss-of-function approaches, which could strengthen the conclusions, does not exist. This is a moderate weakness.

  4. Reviewer #2 (Public review):

    This study uses mass spectrometry to quantify how LPS and IL-4 modify the mouse B cell proteome as naïve cells undergo blastogenesis and enter the cell cycle. This analysis revealed changes in key proteins involved in amino acid transport and cholesterol biosynthesis. Genetic and pharmacological experiments indicated important roles for these metabolic processes in B cell proliferation.

    This work provides new information about the regulation of TI B cell responses by changes in cell metabolism and also a comprehensive mass spectrometry dataset, which will be an important general resource for future studies. The experiments are thorough and carefully carried out. The majority of conclusions are backed up by data that is shown to be highly significant statistically.

    The study would be strengthened by additional experiments to determine whether the detected changes are unique to stimulation with LPS + IL-4 or more generic responses of resting B cells to mitogenic agonists.